Your browser is no longer supported. Please, upgrade your browser.
Settings
PDSB PDS Biotechnology Corporation daily Stock Chart
PDSB [NASD]
PDS Biotechnology Corporation
Index- P/E- EPS (ttm)-11.32 Insider Own6.50% Shs Outstand5.22M Perf Week3.65%
Market Cap32.57M Forward P/E- EPS next Y- Insider Trans- Shs Float1.42M Perf Month0.65%
Income-13.20M PEG- EPS next Q- Inst Own28.10% Short Float9.52% Perf Quarter10.25%
Sales- P/S- EPS this Y38.30% Inst Trans2.52% Short Ratio0.88 Perf Half Y-21.01%
Book/sh6.52 P/B0.96 EPS next Y- ROA-34.70% Target Price1.00 Perf Year-69.41%
Cash/sh5.10 P/C1.22 EPS next 5Y- ROE-44.60% 52W Range5.03 - 23.60 Perf YTD-2.80%
Dividend- P/FCF- EPS past 5Y-34.70% ROI- 52W High-73.94% Beta2.44
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low22.27% ATR0.36
Employees10 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)49.11 Volatility5.75% 5.36%
OptionableYes Debt/Eq0.00 EPS Q/Q110.90% Profit Margin- Rel Volume0.01 Prev Close6.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume152.66K Price6.15
Recom- SMA200.81% SMA50-4.09% SMA200-32.54% Volume727 Change-1.44%
Jul-03-19 08:30AM  PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-19-19 08:30AM  PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® - GM-CSF Combination to Overcome Tumor Immune Suppression GlobeNewswire
May-29-19 09:41AM  Does PDS Biotechnology Corporation (NASDAQ:PDSB) Create Value For Shareholders? Simply Wall St.
08:30AM  PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers GlobeNewswire
May-28-19 08:30AM  PDS Biotechnology to Present at the 9th Annual LD Micro Invitational GlobeNewswire
May-17-19 12:07PM  Learning When To Pick Your Battles Starts With Winning Setups Benzinga -6.74%
May-15-19 08:30AM  PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy GlobeNewswire +41.37%
May-14-19 05:22PM  PDS Biotechnology: 1Q Earnings Snapshot Associated Press
04:10PM  PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-08-19 08:00AM  PDS Biotechnology Appoints Stephen Glover to its Board of Directors GlobeNewswire -8.86%
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. It develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company lead product candidate is PDS0101, an immunotherapeutic for the treatment of cancer. Its synthetic lipid-based immunotherapy platform is Versamune. The company develops Versamune based products for the treatment of cancer. PDS Biotechnology Corporation is based in Berkeley Heights, New Jersey.